Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3803 - Adjuvant concurrent chemoradiotherapy(CRT) plus docetaxel- cisplatin- fluorouracil (DCF) versus CRT plus fluorouracil folinic acid (FUFA) in gastric cancer


08 Oct 2016


Poster Display


Ali Alkan


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


A. Alkan1, D. Mızrak1, E. Karcı1, A. Yaşar1, E.B. Köksoy1, M. Ürün1, T. Kütük2, Y. Ürün1, F. Çay Şenler1, S. Akyürek2, G. Utkan1, A. Demirkazık1, Ş.Ç. Gökçe2, H. Akbulut1

Author affiliations

  • 1 Medical Oncology, Ankara University Medical School-Cebeci Hastaneleri Tıbbi Onkoloji, 06590 - Ankara/TR
  • 2 Radiation Oncology, Ankara University Medical School-Cebeci Hastaneleri Tıbbi Onkoloji, 06590 - Ankara/TR


Abstract 3803


Adjuvant chemoradiotherapy is the optimal management strategy in resectable gastric cancer. There is a debate about the efficacy of more aggressive CRT plus chemotherapy regimens in adjuvant setting. This study aimed to compare the efficacy of adjuvant CRT plus DCF versus CRT plus FUFA in stage III gastric cancer.


Patients with a diagnosis of stage III gastric cancer, treated with adjuvant therapy after curative resection were analyzed. Patients' and disease characteristics, impacts of the regimen on median progression free survival (mPFS) and median overall survival (mOS) were analyzed retrospectively. DCF arm had been treated with 2 cycles DCF (docetaxel 75mg/m2, cisplatin 75mg/m2 on day 1, fluorouracil 750mg/m2 for 4 days every 3 weeks) followed by concurrent CRT with 2 cycles of FUFA (fluorouracil 425mg/m2, folinic acid 20mg/m2, 3 days) and 2 cycles of DCF. FUFA arm was treated with Macdonald regimen (1 cycle of FUFA for 5 days, followed by CRT with 2 cycles of FUFA and further 2 cycles of FUFA.


140 gastric cancer patients, 94 in FUFA and 46 in DCF arms, were evaluated. Patient and disease characteristics were similar between groups. There were more renal toxicity (40% v 7%, p 


There is no DFS or OS advantage of CRT plus DCF over CRT plus FUFA. More aggressive adjuvant therapy with CRT plus DCF is also more toxic than Macdonald regimen.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings